IGC

IGC Pharma, Inc. AMEX Listed May 24, 2006

Healthcare ·Biotechnology ·US · igcpharma.com

$0.32

Pre-mkt $0.31 -0.61%

Mkt Cap $31.3M

52w Low $0.24 29.5% of range 52w High $0.50

50d MA $0.29 200d MA $0.34

P/E (TTM) -3.6x

EV/EBITDA -3.2x

P/B 4.0x

Debt/Equity 0.0x

ROE -89.3%

P/FCF -4.1x

RSI (14) —

ATR (14) —

Beta 0.31

50d MA $0.29

200d MA $0.34

Avg Volume 1.1M

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

SIC Code

2834

CIK (SEC)

1326205

Phone

301 983 0998

10224 Falls Road · Potomac, MD 20854 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 3, 2026	AMC	-0.02	-0.01	+50.0%	—	—	—	—	—	—	—	—
Nov 14, 2025	AMC	-0.02	-0.02	+0.0%	0.36	+2.1%	-5.0%	-1.5%	-2.7%	-4.2%	+0.9%	—
Aug 14, 2025	AMC	-0.03	-0.02	+33.3%	0.36	+2.8%	+2.8%	+2.8%	-2.3%	-3.4%	-2.1%	—
Jun 27, 2025	AMC	-0.02	-0.01	+50.0%	0.31	+0.6%	-1.0%	-0.8%	+1.2%	-1.5%	+4.9%	—
Feb 14, 2025	AMC	-0.03	-0.02	+33.3%	0.31	-0.5%	-2.1%	-3.7%	+0.9%	-0.1%	-3.9%	—
Nov 12, 2024	AMC	-0.02	-0.02	-22.8%	0.38	-5.3%	-3.6%	-2.6%	-5.2%	+3.5%	-2.3%	—
Aug 8, 2024	AMC	-0.03	-0.03	-15.8%	0.39	+4.8%	+4.6%	-0.0%	+0.0%	+4.4%	-0.5%	—
Jun 24, 2024	AMC	-0.00	-0.04	-900.0%	0.47	-6.3%	-8.1%	-2.4%	+1.0%	+2.1%	+1.2%	—
Feb 14, 2024	AMC	-0.04	-0.09	-125.0%	0.30	+3.0%	+0.1%	+1.2%	-2.7%	-3.7%	-3.9%	—
Nov 9, 2023	AMC	—	-0.05	—	0.30	+2.2%	-2.0%	+4.1%	-0.3%	-1.0%	+1.1%	—
Jul 7, 2023	AMC	—	-0.08	—	0.41	-1.3%	-6.6%	+4.4%	-5.0%	+2.6%	-6.2%	—
Jun 30, 2023	AMC	—	-0.13	—	0.31	+2.7%	+4.2%	+4.7%	-1.7%	+22.7%	-6.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 8	Ascendiant Capital	Maintains	Buy → Buy	—	$0.27	$0.28	+3.1%	+3.5%	+7.5%	+0.3%	-1.6%	+4.4%
Feb 23	Ascendiant Capital	Maintains	Buy → Buy	—	$0.26	$0.28	+7.6%	+2.2%	+4.8%	+4.0%	-1.8%	-2.6%
Dec 9	Ascendiant Capital	Maintains	Buy → Buy	—	$0.29	$0.29	-0.4%	+2.5%	+14.8%	-4.1%	+6.0%	-3.9%
Aug 26	Ascendiant Capital	Maintains	Buy → Buy	—	$0.37	$0.38	+0.8%	+4.4%	+15.7%	-5.9%	+1.4%	+3.2%
Mar 6	Alliance Global Partners	Maintains	Buy → Buy	—	$0.28	$0.27	-3.5%	+8.8%	+0.6%	+6.5%	-4.1%	+9.6%
Feb 24	Ascendiant Capital	Maintains	Buy → Buy	—	$0.30	$0.30	-0.2%	-3.9%	+0.4%	-0.6%	-0.7%	+2.8%
Dec 5	Ascendiant Capital	Maintains	Buy → Buy	—	$0.36	$0.36	-0.6%	+0.4%	+2.3%	-1.4%	+2.2%	+3.5%
Sep 3	Ascendiant Capital	Maintains	Buy → Buy	—	$0.36	$0.36	-0.0%	-3.1%	-1.0%	+0.0%	+2.3%	+5.0%
Jul 29	Ascendiant Capital	Maintains	Buy → Buy	—	$0.45	$0.46	+2.4%	+0.9%	-2.4%	+3.2%	+0.8%	-6.1%
Jun 21	Ascendiant Capital	Maintains	Buy → Buy	—	$0.40	$0.42	+3.8%	+36.6%	-14.7%	-8.1%	-2.4%	+1.0%

Data updated apr 25, 2026 3:06pm · Source: massive.com